Charles River Laboratories International (NYSE:CRL) Releases FY 2025 Earnings Guidance

Key Points

• Charles River Laboratories International provided its FY 2025 earnings guidance, projecting earnings per share (EPS) between $9.900-$10.300 and revenue expectations of $3.9 billion-$4.0 billion, exceeding consensus estimates.
• Research analysts raised their price targets for the company's stock, with notable increases from Evercore ISI to $180.00 and Citigroup to $200.00, while the overall consensus rating remains a "Hold."
• In recent trading, CRL stock fell to $150.12, with institutional investors owning 98.91% of shares, indicating strong institutional confidence despite the stock's recent decline.

Charles River Laboratories International (NYSE:CRL - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 9.900-10.300 for the period, compared to the consensus EPS estimate of 9.600. The company issued revenue guidance of $3.9 billion-$4.0 billion, compared to the consensus revenue estimate of $3.9 billion.

Analysts Set New Price Targets

CRL has been the subject of a number of research reports. Evercore ISI lifted their target price on shares of Charles River Laboratories International from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 9th. Barclays raised their price target on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a research report on Thursday. Wall Street Zen lowered Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Saturday, July 5th. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a research note on Wednesday, May 14th. Finally, Citigroup upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and upped their price target for the company from $150.00 to $200.00 in a research note on Wednesday, July 9th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $175.31.

Charles River Laboratories International Price Performance

CRL stock traded down $0.21 during midday trading on Thursday, reaching $150.12. 754,899 shares of the company's stock traded hands, compared to its average volume of 1,287,542. Charles River Laboratories International has a 1-year low of $91.86 and a 1-year high of $230.02. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.78. The company has a market cap of $7.37 billion, a price-to-earnings ratio of -230.76, a PEG ratio of 5.67 and a beta of 1.48. The company has a 50-day simple moving average of $155.03 and a two-hundred day simple moving average of $149.60.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, beating analysts' consensus estimates of $2.50 by $0.62. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. Charles River Laboratories International's revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.80 EPS. On average, analysts anticipate that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president directly owned 19,513 shares in the company, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.30% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Charles River Laboratories International stock. Empowered Funds LLC bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 2,776 shares of the medical research company's stock, valued at approximately $418,000. Institutional investors and hedge funds own 98.91% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.